Pralsetinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 64 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Pralsetinib - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Pralsetinib is an orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion products. RET gene mutations and translocations result in...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Pralsetinib is an orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion products. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role...

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Pralsetinib is an orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion products. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers.

Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib, have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Pralsetinib (BLU-667) and selpercatinib (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[rx]

Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment of metastatic RET-fusion positive non-small cell lung cancer. It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.

Mechanism of action

Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase containing extracellular, transmembrane, and intracellular domains whose activity is required for normal kidney and nervous system development. Constitutive RET activation is achieved through chromosomal rearrangements producing 5′ fusions of dimerizable domains to the 3′ RET tyrosine kinase domain leading to constitutive dimerization and subsequent autophosphorylation; the most common fusions are KIF5B-RET and CCDC6-RET, although more than 35 genes have been reported to fuse with RET. Constitutive activation leads to increased downstream signalling and is associated with tumour invasion, migration, and proliferation.[rx]

Pralsetinib (formerly referred to as BLU-667) was developed through screening more than 10,000 agnostically designed kinase inhibitors followed by extensive chemical modification to improve its properties. Pralsetinib displays in vitro IC50 values for both WT RET as well as several mutant forms, including CCDC6-RET, in the range of 0.3-0.4 nmol/L, and is 100-fold more selective for RET kinase over 96% of 371 kinases tested.5 It is this specific inhibition of RET kinase that is associated with anti-tumour activity and clinical benefit in patients.

Despite increased selectivity for RET over other kinases, pralsetinib has been reported to inhibit DDR1, TRKC, FLT3, JAK1-2, TRKA, VEGFR2, PDGFRb, and FGFR1-2 at clinically relevant concentrations. The significance of these findings remains uncertain.[rx]

Pralsetinib exerts an anti-tumour effect through specific inhibition of the rearranged during transfection (RET) tyrosine kinase, including multiple distinct oncogenic RET fusions, mutated RET kinase domains harbouring gatekeeper mutations, and in RET kinases with a variety of activating single point mutations. Due to pralsetinib’s high selectivity for RET over other kinases, both in vitro and in vivo,[rx] pralsetinib has been described as having a better safety profile compared to previously used multi-kinase inhibitors. Despite this, pralsetinib use may increase the risk of hypertension, hemorrhagic events, impaired wound healing, hepatotoxicity, interstitial lung disease/pneumonitis, and embryo-fetal toxicity.[rx]

Indications

  • Treatment of lung cancer (small cell and non-small cell lung cancer )
  • Pralsetinib is a RET receptor tyrosine kinase inhibitor for the treatment of metastatic RET-driven non-small cell lung cancer.
  • Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.
  • Treatment of thyroid cancer
  • Pralsetinib is approved to treat: Medullary thyroid cancer that has a mutation in the RETgene and is advanced or metastatic. It is used in adults and children aged 12 years and older who need systemic therapy. Non-small cell lung cancer has a RET fusion gene and is metastatic. It is used in adults. Thyroid cancer that has a RET fusion gene and is metastatic or advanced. It is used in adults and children aged 12 years and older who need systemic therapy, including those who received radioactive iodine and it did not work or is no longer working.
  • Pralsetinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients who are confirmed to possess a rearranged during transfection (RET) gene fusion, as determined by an FDA approved test. It is also indicated in adult and pediatric patients 12 years of age and older for the treatment of advanced or metastatic RET-mutant medullary thyroid cancer, and in this same population for the treatment of advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and for whom radioactive iodine is not appropriate.[rx]
  • Advanced RET-fusion Non Small Cell Lung Cancer
  • Advanced RET-fusion thyroid cancer
  • Advanced RET-mutant medullary thyroid cancer
  • Metastatic RET-fusion Non Small Cell Lung Cancer
  • Metastatic RET-fusion thyroid cancer
  • Metastatic RET-mutant medullary thyroid cancer

Use in Cancer

Pralsetinib is approved to treat:

  • Medullary thyroid cancer has a mutation in the RET gene and is advanced or metastatic. It is used in adults and children aged 12 years and older who need systemic therapy.
  • Non-small cell lung cancer has a RET fusion gene and is metastatic. It is used in adults.
  • Thyroid cancer that has a RET fusion gene and is metastatic or advanced. It is used in adults and children aged 12 years and older who need systemic therapy, including those who received radioactive iodine and it did not work or is no longer working.

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that pralsetinib provides a clinical benefit in these patients.

Pralsetinib is also being studied in the treatment of other types of cancer.

Contraindications

  • high blood pressure
  • bleeding
  • recent operation
  • abnormal liver function tests
  • impaired wound healing
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • lung tissue problem

Dosage

Strengths: 100 mg

Non-Small Cell Lung Cancer

  • 400 mg orally once a day
  • Duration of therapy: Continue until disease progression or unacceptable toxicity
  • Select patients based on the presence of a RET (rearranged during transfection) gene fusion.
  • Information on FDA-approved tests for RET gene fusion is available at http://www.fda.gov/CompanionDiagnostics.

Thyroid Cancer

  • 400 mg orally once a day
  • Duration of therapy: Continue until disease progression or unacceptable toxicity
  • Select patients based on the presence of a RET (rearranged during transfection) gene fusion (thyroid cancer) or RET gene mutation (MTC).
  • However, FDA-approved gene fusion tests for RET gene fusion (thyroid cancer) and RET gene mutations are currently not available.
  • For the treatment of advanced or metastatic RET mutant medullary thyroid cancer (MTC) who require systemic therapy.
  • For the treatment of advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Pediatric Dose for Thyroid Cancer

  • 12 years or older: 400 mg orally once a day
  • Duration of therapy: Continue until disease progression or unacceptable toxicity
  • Select patients based on the presence of a RET (rearranged during transfection) gene fusion (thyroid cancer) or RET gene mutation (MTC).
  • However, FDA-approved gene fusion tests for RET gene fusion (thyroid cancer) and RET gene mutations are currently not available.
  • For the treatment of advanced or metastatic RET mutant medullary thyroid cancer (MTC) who require systemic therapy.
  • For the treatment of advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Renal Dose Adjustments

  • Mild to moderate renal impairment (CrCl 30 to less than 90 mL/min): No adjustment recommended.
  • Severe renal impairment (CrCl 15 to less than 30 mL/min): Data not available
  • ESRD: Data not available

Liver Dose Adjustments

  • Mild hepatic impairment (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin less than or equal to upper limit of normal [ULN] and AST greater than ULN; or total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 1 to 1.5 x ULN and any AST): No adjustment recommended.
  • Moderate hepatic impairment (total bilirubin greater than 1.5 to 3 x ULN and any AST: Data not available
  • Severe hepatic impairment (total bilirubin greater than 3 x ULN and any AST): Data not available

Dose Adjustments

DOSE REDUCTIONS FOR ADVERSE REACTIONS:

  • First dose reduction: 300 mg orally once a day
  • Second dose reduction: 200 mg orally once a day
  • Third dose reduction: 100 mg orally once a day
  • Discontinue therapy in patients unable to tolerate 100 mg/day.

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
ILD/PNEUMONITIS:

  • Grade 1 or 2: Withhold therapy until resolution; resume at reduced dose
  • Grade 3 or 4 or recurrent: Permanently discontinue for confirmed ILD/pneumonitis

HYPERTENSION:

  • Grade 3: Withhold therapy for Grade 3 hypertension that persists despite optimal antihypertensives; resume at reduced dose when hypertension is controlled
  • Grade 4: Permanently discontinue therapy

HEPATOTOXICITY:

  • Grade 3 or 4: Withhold therapy, monitor transaminases weekly until recovery to Grade 1 or baseline; resume at reduced dose; if hepatotoxicity recurs at Grade 3 or higher, discontinue.

HEMORRHAGIC EVENTS:

  • Grade 3 or 4: Withhold therapy until recovery to baseline, Grade 0, or 1
  • Severe or life-threatening hemorrhagic events: Discontinue therapy

OTHER ADVERSE REACTIONS:

  • Grade 3 or 4: Withhold therapy until improvement to Grade 2 or less; resume at reduced dose
  • Recurrent Grade 4: Permanently discontinue

COADMINISTRATION WITH COMBINED P-GLYCOPROTEIN (P-gp) AND STRONG CYP450 3A INHIBITORS:

  • Avoid coadministration with combined P-gp and strong CYP450 3A inhibitors.
  • If coadministration cannot be avoided, reduce dose of pralsetinib (if current dose is 300 mg/day or 400 mg/day reduce dose to 200 mg/day; if current dose is 200 mg/day reduce dose to 100 mg/day).
  • After combined P-gp and strong CYP450 3A inhibitor has been discontinued for 3 to 5 elimination half-lives, resume pralsetinib at dose taken prior to initiating combined P-gp and strong CYP450 3A inhibitor

COADMINISTRATION WITH STRONG CYP450 3A INDUCERS:

  • Avoid coadministration with strong CYP450 3A inducers.
  • If coadministration with a strong CYP450 3A inducer cannot be avoided, increase the starting dose of pralsetinib to double the current dose starting on Day 7 of coadministration.
  • After CYP450 3A inducer has been discontinued for at least 14 days, resume pralsetinib at dose taken prior to initiating CYP450 3A inducer.

Administration advice:

  • Take orally on an empty stomach; no food should be consumed for at least 2 hours before and at least 1 hour after dosing

Side Effects

The Most Common

  • constipation
  • diarrhea
  • dry mouth
  • muscle or bone pain
  • swelling of hands, ankles, or feet
  • confusion, headache, shortness of breath, dizziness, or chest pain
  • fever, shortness of breath, or cough
  • pale skin, fatigue, or shortness of breath
  • yellowing of skin or eyes, dark-colored urine, bleeding or bruising more easily than normal, loss of appetite, decreased energy, or pain on the right side of the stomach area
  • black and tarry stools
  • red blood in stools
  • bloody vomit
  • vomiting material that looks like coffee grounds
  • coughing up blood
  • unusual bleeding or bruising
  • unusual vaginal bleeding
  • frequent nose bleeds
  • drowsiness, confusion, headache, or difficulty speaking
  • Bone pain
  • burning, numbness, tingling, or painful sensations
  • change in taste
  • constipation
  • decreased appetite

More common

  • Bleeding gums
  • blurred vision
  • chest pain
  • chills
  • cough
  • coughing up blood
  • dark urine
  • decrease or change in the amount of urine
  • difficulty in breathing or swallowing
  • dizziness
  • fainting
  • fast or slow heartbeat
  • fever
  • general feeling of discomfort or illness
  • headache
  • increased menstrual flow or vaginal bleeding
  • irregular pulse
  • joint pain, stiffness, or swelling
  • loss of appetite
  • lower back, side, or stomach pain
  • nausea
  • nervousness
  • nosebleeds
  • paralysis
  • pounding in the ears
  • prolonged bleeding from cuts
  • rapid weight gain
  • red or black, tarry stools
  • red or dark brown urine
  • slow or fast heartbeat
  • stomach pain, severe
  • swelling around the eye
  • swelling of the eyelids
  • swelling of the feet or lower legs
  • swelling or puffiness of the face
  • thickening of bronchial secretions
  • unusual tiredness or weakness
  • vomiting
  • yellow eyes or skin

Rare

  • Black, tarry stools
  • bladder pain
  • bloody or cloudy urine
  • chest pain or tightness
  • confusion
  • difficult, burning, or painful urination
  • frequent urge to urinate
  • lightheadedness
  • lower back or side pain
  • pale skin
  • sneezing
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen glands
  • unusual bleeding or bruising
  • difficulty in moving
  • dry mouth
  • joint pain
  • lack or loss of strength
  • loss of taste
  • muscle aching or cramping
  • muscle pains or stiffness
  • neck pain
  • pain, swelling, or redness in the joints
  • swelling or inflammation of the mouth
  • tenderness
  • unsteadiness or awkwardness
  • watery or bloody diarrhea
  • weakness in the arms, hands, legs, or feet

Drug Interactions

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on findings from animal studies and its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman. Pregnancy status should be verified prior to initiating therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Females of reproductive potential should use effective nonhormonal contraception during therapy and for 2 weeks after; this drug may render hormonal contraceptives ineffective. Male patients with female partners of reproductive potential should use effective contraception during therapy and for 1 week after the final dose.

Lactation

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

How should this medicine be used?

Pralsetinib comes as a capsule to take by mouth. It is usually taken once daily on an empty stomach, at least 2 hours before and at least 1 hour after a meal. Take pralsetinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take pralsetinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

If you vomit after taking pralsetinib, do not take another dose. Continue your regular dosing schedule.

Your doctor may decrease your dose or temporarily or permanently stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with pralsetinib. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking pralsetinib,

  • tell your doctor and pharmacist if you are allergic to pralsetinib, any other medications, or any of the ingredients in pralsetinib capsules. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antifungal medications including itraconazole (Onmel, Sporanox) and ketoconazole; clarithromycin (in Biaxin); certain HIV medications such as efavirenz (Sustiva, in Atripla, Symfi), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, Viekira Pak), and saquinavir (Invirase); oxcarbazepine (Oxtellar XR, Trileptal); phenobarbital; phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Oseni, Duetact); rifabutin (Mycobutin); and rifampin (Rifadin, Rimactane, in Rifater). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor what herbal products you are taking, especially St. John’s wort.
  • tell your doctor if you have or have ever had lung or breathing problems other than lung cancer, bleeding problems, high blood pressure, or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or if you plan to father a child. Pralsetinib may interfere with the action of hormonal contraceptives (birth control pills, patches, rings, implants, or injections), so you should not use these as your only method of birth control during your treatment. You must use non-hormonal birth control such as a barrier method (a device that blocks sperm from entering the uterus such as a condom or a diaphragm). Ask your doctor to help you choose a method of birth control that will work for you. If you are female, you will need to have a pregnancy test before you start treatment, and you should use non-hormonal birth control to prevent pregnancy during your treatment and for 2 weeks after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control to prevent pregnancy during your treatment and for 1 week after your final dose. You should know that this medication may decrease fertility in men and women; however, you should not assume that you cannot get pregnant or that you cannot get someone else pregnant. If you or your partner becomes pregnant while taking pralsetinib, call your doctor. Pralsetinib may harm the fetus.
  • tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while taking trametinib and for 1 week after your final dose.
  • you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of taking pralsetinib.
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking pralsetinib. Your doctor may tell you not to take pralsetinib 5 days before your surgery and will tell you when to start taking the medication again.
  • you should know that your blood pressure may increase during your treatment with pralsetinib. Your doctor will monitor your blood pressure carefully, and may prescribe medication to treat high blood pressure if it develops.
  • you should know that you may experience tumor lysis syndrome (TLS; a condition caused by the fast breakdown of cancer cells that can cause kidney failure and other complications) during your treatment with pralsetinib. To help reduce your risk of experiencing TLS, your doctor may ask you to drink water before and during your treatment, and each time your dose is increased. In addition, your doctor will give you a medication to take before starting and during your treatment to help prevent this side effect. If you experience any of the following symptoms of TLS, call your doctor immediately: fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Pralsetinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of action Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase containing extracellular, transmembrane, and intracellular domains whose activity is required for normal kidney and nervous system development. Constitutive RET activation is achieved through chromosomal rearrangements producing 5' fusions of dimerizable domains to the 3' RET tyrosine kinase domain leading to constitutive dimerization and subsequent autophosphorylation; the most common fusions are KIF5B-RET and CCDC6-RET, although more than 35 genes have been reported to fuse with RET. Constitutive activation leads to increased downstream signalling and is associated with tumour invasion, migration, and proliferation.[rx] Pralsetinib (formerly referred to as BLU-667) was developed through screening more than 10,000 agnostically designed kinase inhibitors followed by extensive chemical modification to improve its properties. Pralsetinib displays in vitro IC50 values for both WT RET as well as several mutant forms, including CCDC6-RET, in the range of 0.3-0.4 nmol/L, and is 100-fold more selective for RET kinase over 96% of 371 kinases tested.5 It is this specific inhibition of RET kinase that is associated with anti-tumour activity and clinical benefit in patients. Despite increased selectivity for RET over other kinases, pralsetinib has been reported to inhibit DDR1, TRKC, FLT3, JAK1-2, TRKA, VEGFR2, PDGFRb, and FGFR1-2 at clinically relevant concentrations. The significance of these findings remains uncertain.[rx] Pralsetinib exerts an anti-tumour effect through specific inhibition of the rearranged during transfection (RET) tyrosine kinase, including multiple distinct oncogenic RET fusions, mutated RET kinase domains harbouring gatekeeper mutations, and in RET kinases with a variety of activating single point mutations. Due to pralsetinib's high selectivity for RET over other kinases, both in vitro and in vivo,[rx] pralsetinib has been described as having a better safety profile compared to previously used multi-kinase inhibitors. Despite this, pralsetinib use may increase the risk of hypertension, hemorrhagic events, impaired wound healing, hepatotoxicity, interstitial lung disease/pneumonitis, and embryo-fetal toxicity.[rx] Indications Treatment of lung cancer (small cell and non-small cell lung cancer ) Pralsetinib is a RET receptor tyrosine kinase inhibitor for the treatment of metastatic RET-driven non-small cell lung cancer. Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. Treatment of thyroid cancer Pralsetinib is approved to treat: Medullary thyroid cancer that has a mutation in the RETgene and is advanced or metastatic. It is used in adults and children aged 12 years and older who need systemic therapy. Non-small cell lung cancer has a RET fusion gene and is metastatic. It is used in adults. Thyroid cancer that has a RET fusion gene and is metastatic or advanced. It is used in adults and children aged 12 years and older who need systemic therapy, including those who received radioactive iodine and it did not work or is no longer working. Pralsetinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients who are confirmed to possess a rearranged during transfection (RET) gene fusion, as determined by an FDA approved test. It is also indicated in adult and pediatric patients 12 years of age and older for the treatment of advanced or metastatic RET-mutant medullary thyroid cancer, and in this same population for the treatment of advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and for whom radioactive iodine is not appropriate.[rx] Advanced RET-fusion Non Small Cell Lung Cancer Advanced RET-fusion thyroid cancer Advanced RET-mutant medullary thyroid cancer Metastatic RET-fusion Non Small Cell Lung Cancer Metastatic RET-fusion thyroid cancer Metastatic RET-mutant medullary thyroid cancer Use in Cancer Pralsetinib is approved to treat: Medullary thyroid cancer has a mutation in the RET gene and is advanced or metastatic. It is used in adults and children aged 12 years and older who need systemic therapy. Non-small cell lung cancer has a RET fusion gene and is metastatic. It is used in adults. Thyroid cancer that has a RET fusion gene and is metastatic or advanced. It is used in adults and children aged 12 years and older who need systemic therapy, including those who received radioactive iodine and it did not work or is no longer working. ¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that pralsetinib provides a clinical benefit in these patients. Pralsetinib is also being studied in the treatment of other types of cancer. Contraindications high blood pressure bleeding recent operation abnormal liver function tests impaired wound healing pregnancy a patient who is producing milk and breastfeeding lung tissue problem Dosage Strengths: 100 mg Non-Small Cell Lung Cancer 400 mg orally once a day Duration of therapy: Continue until disease progression or unacceptable toxicity Select patients based on the presence of a RET (rearranged during transfection) gene fusion. Information on FDA-approved tests for RET gene fusion is available at http://www.fda.gov/CompanionDiagnostics. Thyroid Cancer 400 mg orally once a day Duration of therapy: Continue until disease progression or unacceptable toxicity Select patients based on the presence of a RET (rearranged during transfection) gene fusion (thyroid cancer) or RET gene mutation (MTC). However, FDA-approved gene fusion tests for RET gene fusion (thyroid cancer) and RET gene mutations are currently not available. For the treatment of advanced or metastatic RET mutant medullary thyroid cancer (MTC) who require systemic therapy. For the treatment of advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Pediatric Dose for Thyroid Cancer 12 years or older: 400 mg orally once a day Duration of therapy: Continue until disease progression or unacceptable toxicity Select patients based on the presence of a RET (rearranged during transfection) gene fusion (thyroid cancer) or RET gene mutation (MTC). However, FDA-approved gene fusion tests for RET gene fusion (thyroid cancer) and RET gene mutations are currently not available. For the treatment of advanced or metastatic RET mutant medullary thyroid cancer (MTC) who require systemic therapy. For the treatment of advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Renal Dose Adjustments Mild to moderate renal impairment (CrCl 30 to less than 90 mL/min): No adjustment recommended. Severe renal impairment (CrCl 15 to less than 30 mL/min): Data not available ESRD: Data not available Liver Dose Adjustments Mild hepatic impairment (total bilirubin less than or equal to upper limit of normal [ULN] and AST greater than ULN; or total bilirubin greater than 1 to 1.5 x ULN and any AST): No adjustment recommended. Moderate hepatic impairment (total bilirubin greater than 1.5 to 3 x ULN and any AST: Data not available Severe hepatic impairment (total bilirubin greater than 3 x ULN and any AST): Data not available Dose Adjustments DOSE REDUCTIONS FOR ADVERSE REACTIONS: First dose reduction: 300 mg orally once a day Second dose reduction: 200 mg orally once a day Third dose reduction: 100 mg orally once a day Discontinue therapy in patients unable to tolerate 100 mg/day. DOSE MODIFICATIONS FOR ADVERSE REACTIONS: ILD/PNEUMONITIS: Grade 1 or 2: Withhold therapy until resolution; resume at reduced dose Grade 3 or 4 or recurrent: Permanently discontinue for confirmed ILD/pneumonitis HYPERTENSION: Grade 3: Withhold therapy for Grade 3 hypertension that persists despite optimal antihypertensives; resume at reduced dose when hypertension is controlled Grade 4: Permanently discontinue therapy HEPATOTOXICITY: Grade 3 or 4: Withhold therapy, monitor transaminases weekly until recovery to Grade 1 or baseline; resume at reduced dose; if hepatotoxicity recurs at Grade 3 or higher, discontinue. HEMORRHAGIC EVENTS: Grade 3 or 4: Withhold therapy until recovery to baseline, Grade 0, or 1 Severe or life-threatening hemorrhagic events: Discontinue therapy OTHER ADVERSE REACTIONS: Grade 3 or 4: Withhold therapy until improvement to Grade 2 or less; resume at reduced dose Recurrent Grade 4: Permanently discontinue COADMINISTRATION WITH COMBINED P-GLYCOPROTEIN (P-gp) AND STRONG CYP450 3A INHIBITORS: Avoid coadministration with combined P-gp and strong CYP450 3A inhibitors. If coadministration cannot be avoided, reduce dose of pralsetinib (if current dose is 300 mg/day or 400 mg/day reduce dose to 200 mg/day; if current dose is 200 mg/day reduce dose to 100 mg/day). After combined P-gp and strong CYP450 3A inhibitor has been discontinued for 3 to 5 elimination half-lives, resume pralsetinib at dose taken prior to initiating combined P-gp and strong CYP450 3A inhibitor COADMINISTRATION WITH STRONG CYP450 3A INDUCERS: Avoid coadministration with strong CYP450 3A inducers. If coadministration with a strong CYP450 3A inducer cannot be avoided, increase the starting dose of pralsetinib to double the current dose starting on Day 7 of coadministration. After CYP450 3A inducer has been discontinued for at least 14 days, resume pralsetinib at dose taken prior to initiating CYP450 3A inducer. Administration advice: Take orally on an empty stomach; no food should be consumed for at least 2 hours before and at least 1 hour after dosing Side Effects The Most Common constipation diarrhea dry mouth muscle or bone pain swelling of hands, ankles, or feet confusion, headache, shortness of breath, dizziness, or chest pain fever, shortness of breath, or cough pale skin, fatigue, or shortness of breath yellowing of skin or eyes, dark-colored urine, bleeding or bruising more easily than normal, loss of appetite, decreased energy, or pain on the right side of the stomach area black and tarry stools red blood in stools bloody vomit vomiting material that looks like coffee grounds coughing up blood unusual bleeding or bruising unusual vaginal bleeding frequent nose bleeds drowsiness, confusion, headache, or difficulty speaking Bone pain burning, numbness, tingling, or painful sensations change in taste constipation decreased appetite More common Bleeding gums blurred vision chest pain chills cough coughing up blood dark urine decrease or change in the amount of urine difficulty in breathing or swallowing dizziness fainting fast or slow heartbeat fever general feeling of discomfort or illness headache increased menstrual flow or vaginal bleeding irregular pulse joint pain, stiffness, or swelling loss of appetite lower back, side, or stomach pain nausea nervousness nosebleeds paralysis pounding in the ears prolonged bleeding from cuts rapid weight gain red or black, tarry stools red or dark brown urine slow or fast heartbeat stomach pain, severe swelling around the eye swelling of the eyelids swelling of the feet or lower legs swelling or puffiness of the face thickening of bronchial secretions unusual tiredness or weakness vomiting yellow eyes or skin Rare Black, tarry stools bladder pain bloody or cloudy urine chest pain or tightness confusion difficult, burning, or painful urination frequent urge to urinate lightheadedness lower back or side pain pale skin sneezing sore throat sores, ulcers, or white spots on the lips or in the mouth swollen glands unusual bleeding or bruising difficulty in moving dry mouth joint pain lack or loss of strength loss of taste muscle aching or cramping muscle pains or stiffness neck pain pain, swelling, or redness in the joints swelling or inflammation of the mouth tenderness unsteadiness or awkwardness watery or bloody diarrhea weakness in the arms, hands, legs, or feet Drug Interactions DRUG INTERACTION Abametapir The serum concentration of Pralsetinib can be increased when it is combined with Abametapir. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Pralsetinib. Abrocitinib The serum concentration of Pralsetinib can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Pralsetinib. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Pralsetinib. Acetohexamide The metabolism of Acetohexamide can be decreased when combined with Pralsetinib. Acetylsalicylic acid The metabolism of Acetylsalicylic acid can be decreased when combined with Pralsetinib. Acyclovir The excretion of Acyclovir can be decreased when combined with Pralsetinib. Adefovir dipivoxil The excretion of Adefovir dipivoxil can be decreased when combined with Pralsetinib. Afatinib The serum concentration of Pralsetinib can be increased when it is combined with Afatinib. Albendazole The metabolism of Albendazole can be increased when combined with Pralsetinib. Alectinib The metabolism of Alectinib can be increased when combined with Pralsetinib. Alfentanil The metabolism of Alfentanil can be decreased when combined with Pralsetinib. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Pralsetinib. Allopurinol Pralsetinib may decrease the excretion rate of Allopurinol which could result in a higher serum level. Almotriptan The metabolism of Almotriptan can be decreased when combined with Pralsetinib. Alosetron The metabolism of Alosetron can be decreased when combined with Pralsetinib. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Pralsetinib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Pralsetinib. Alprostadil The excretion of Alprostadil can be decreased when combined with Pralsetinib. Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Pralsetinib. Aminohippuric acid The excretion of Aminohippuric acid can be decreased when combined with Pralsetinib. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Pralsetinib. Aminophylline The metabolism of Aminophylline can be increased when combined with Pralsetinib. Amiodarone The serum concentration of Pralsetinib can be increased when it is combined with Amiodarone. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Pralsetinib. Amlodipine The metabolism of Amlodipine can be increased when combined with Pralsetinib. Amodiaquine The metabolism of Amodiaquine can be decreased when combined with Pralsetinib. Amprenavir The serum concentration of Pralsetinib can be increased when it is combined with Amprenavir. Anastrozole The metabolism of Anastrozole can be decreased when combined with Pralsetinib. Antipyrine The metabolism of Antipyrine can be decreased when combined with Pralsetinib. Apalutamide The serum concentration of Pralsetinib can be decreased when it is combined with Apalutamide. Apixaban Pralsetinib may decrease the excretion rate of Apixaban which could result in a higher serum level. Apomorphine The metabolism of Apomorphine can be decreased when combined with Pralsetinib. Aprepitant The metabolism of Pralsetinib can be decreased when combined with Aprepitant. Arformoterol The metabolism of Arformoterol can be decreased when combined with Pralsetinib. Aripiprazole The metabolism of Aripiprazole can be increased when combined with Pralsetinib. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Pralsetinib. Arsenic trioxide The serum concentration of Pralsetinib can be increased when it is combined with Arsenic trioxide. Artemether The metabolism of Artemether can be decreased when combined with Pralsetinib. Articaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Articaine. Asciminib The serum concentration of Pralsetinib can be increased when it is combined with Asciminib. Astemizole The metabolism of Astemizole can be increased when combined with Pralsetinib. Asunaprevir The serum concentration of Pralsetinib can be increased when it is combined with Asunaprevir. Atazanavir The serum concentration of Pralsetinib can be increased when it is combined with Atazanavir. Atenolol Pralsetinib may decrease the excretion rate of Atenolol which could result in a higher serum level. Atogepant The serum concentration of Atogepant can be increased when it is combined with Pralsetinib. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Pralsetinib. Atropine Pralsetinib may decrease the excretion rate of Atropine which could result in a higher serum level. Avanafil The serum concentration of Avanafil can be increased when it is combined with Pralsetinib. Avapritinib The metabolism of Avapritinib can be decreased when combined with Pralsetinib. Avatrombopag Avatrombopag may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Axitinib The serum concentration of Axitinib can be increased when it is combined with Pralsetinib. Azelastine The metabolism of Azelastine can be decreased when combined with Pralsetinib. Azithromycin The metabolism of Azithromycin can be increased when combined with Pralsetinib. Baricitinib The excretion of Baricitinib can be decreased when combined with Pralsetinib. Beclomethasone Beclomethasone dipropionate may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Belantamab Pralsetinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Belinostat The serum concentration of Belinostat can be increased when it is combined with Pralsetinib. Belumosudil The serum concentration of Pralsetinib can be increased when it is combined with Belumosudil. Bempedoic acid The excretion of Bempedoic acid can be decreased when combined with Pralsetinib. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Pralsetinib. Benzocaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Benzyl alcohol. Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Pralsetinib. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Pralsetinib. Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Pralsetinib. Bexarotene The metabolism of Bexarotene can be decreased when combined with Pralsetinib. Bicalutamide The metabolism of Bicalutamide can be increased when combined with Pralsetinib. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Pralsetinib. Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Pralsetinib. Boceprevir The serum concentration of Pralsetinib can be increased when it is combined with Boceprevir. Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Pralsetinib. Bosentan The risk or severity of liver damage can be increased when Bosentan is combined with Pralsetinib. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Pralsetinib. Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Pralsetinib. Brigatinib The metabolism of Brigatinib can be increased when combined with Pralsetinib. Brincidofovir The serum concentration of Brincidofovir can be increased when it is combined with Pralsetinib. Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Pralsetinib. Budesonide Pralsetinib may decrease the excretion rate of Budesonide which could result in a higher serum level. Bupivacaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Bupivacaine. Buprenorphine Buprenorphine may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Bupropion The metabolism of Bupropion can be decreased when combined with Pralsetinib. Buspirone The metabolism of Buspirone can be decreased when combined with Pralsetinib. Busulfan The metabolism of Busulfan can be increased when combined with Pralsetinib. Butacaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Butamben. Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Pralsetinib. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Pralsetinib. Cabozantinib The metabolism of Cabozantinib can be decreased when combined with Pralsetinib. Caffeine Caffeine may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Canagliflozin The serum concentration of Pralsetinib can be increased when it is combined with Canagliflozin. Candesartan The metabolism of Candesartan cilexetil can be decreased when combined with Pralsetinib. Cannabidiol Cannabidiol may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Capecitabine The metabolism of Capecitabine can be decreased when combined with Pralsetinib. Capmatinib The serum concentration of Capmatinib can be decreased when it is combined with Pralsetinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Capsaicin. Captopril The excretion of Captopril can be decreased when combined with Pralsetinib. Carbamazepine The serum concentration of Pralsetinib can be decreased when it is combined with Carbamazepine. Carfilzomib The serum concentration of Pralsetinib can be increased when it is combined with Carfilzomib. Carvedilol The serum concentration of Pralsetinib can be increased when it is combined with Carvedilol. Caspofungin The excretion of Caspofungin can be decreased when combined with Pralsetinib. Cefaclor Pralsetinib may decrease the excretion rate of Cefaclor which could result in a higher serum level. Cefazolin The excretion of Cefazolin can be decreased when combined with Pralsetinib. Cefdinir The excretion of Cefdinir can be decreased when combined with Pralsetinib. Cefotiam The excretion of Cefotiam can be decreased when combined with Pralsetinib. Cefradine The excretion of Cefradine can be decreased when combined with Pralsetinib. Ceftibuten The excretion of Ceftibuten can be decreased when combined with Pralsetinib. Ceftizoxime The excretion of Ceftizoxime can be decreased when combined with Pralsetinib. Celecoxib Pralsetinib may decrease the excretion rate of Celecoxib which could result in a higher serum level. Cenobamate The serum concentration of Pralsetinib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Cephalexin can be increased when combined with Pralsetinib. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Pralsetinib. Cerivastatin Pralsetinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Chloroprocaine. Chloroquine The metabolism of Chloroquine can be decreased when combined with Pralsetinib. Chlorpheniramine The metabolism of Chlorpheniramine can be decreased when combined with Pralsetinib. Chlorpromazine The risk or severity of liver damage can be increased when Chlorpromazine is combined with Pralsetinib. Chlorpropamide The metabolism of Chlorpropamide can be decreased when combined with Pralsetinib. Cholecystokinin The excretion of Cholecystokinin can be decreased when combined with Pralsetinib. Cholesterol Cholesterol may increase the excretion rate of Pralsetinib which could result in a lower serum level and potentially a reduction in efficacy. Cholic Acid Pralsetinib may decrease the excretion rate of Cholic Acid which could result in a higher serum level. Cidofovir The excretion of Cidofovir can be decreased when combined with Pralsetinib. Cilostazol The metabolism of Cilostazol can be decreased when combined with Pralsetinib. Cimetidine The risk or severity of liver damage can be increased when Cimetidine is combined with Pralsetinib. Cinchocaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Cinchocaine. Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Pralsetinib. Ciprofloxacin The metabolism of Pralsetinib can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Cisapride can be increased when combined with Pralsetinib. Cladribine Pralsetinib may decrease the excretion rate of Cladribine which could result in a higher serum level. Clarithromycin The serum concentration of Pralsetinib can be increased when it is combined with Clarithromycin. Clindamycin The metabolism of Clindamycin can be increased when combined with Pralsetinib. Clobazam The serum concentration of Clobazam can be increased when it is combined with Pralsetinib. Clofarabine Pralsetinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine The serum concentration of Pralsetinib can be increased when it is combined with Clofazimine. Clomifene The serum concentration of Clomifene can be increased when it is combined with Pralsetinib. Clomipramine The metabolism of Clomipramine can be increased when combined with Pralsetinib. Clonazepam The metabolism of Clonazepam can be increased when combined with Pralsetinib. Clonidine The metabolism of Clonidine can be increased when combined with Pralsetinib. Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Pralsetinib. Clozapine The metabolism of Pralsetinib can be decreased when combined with Clozapine. Cobicistat The serum concentration of Pralsetinib can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Pralsetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Cocaine. Colchicine The serum concentration of Colchicine can be increased when it is combined with Pralsetinib. Conivaptan The serum concentration of Pralsetinib can be increased when it is combined with Conivaptan. Conjugated Pralsetinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Pralsetinib. Crizotinib The serum concentration of Pralsetinib can be increased when it is combined with Crizotinib. Curcumin The serum concentration of Pralsetinib can be increased when it is combined with Curcumin. Cyclophosphamide The metabolism of Cyclophosphamide can be increased when combined with Pralsetinib. Cyclosporine The serum concentration of Pralsetinib can be increased when it is combined with Cyclosporine. Cyproterone acetate The metabolism of Cyproterone acetate can be increased when combined with Pralsetinib. Dabigatran etexilate The serum concentration of Dabigatran etexilate can be increased when it is combined with Pralsetinib. Dabrafenib The serum concentration of Pralsetinib can be decreased when it is combined with Dabrafenib. Daclatasvir The serum concentration of Pralsetinib can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Pralsetinib can be increased when it is combined with Dacomitinib. Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Pralsetinib. Danazol The serum concentration of Pralsetinib can be increased when it is combined with Danazol. Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Pralsetinib. Dapsone The metabolism of Dapsone can be decreased when combined with Pralsetinib. Daptomycin The serum concentration of Daptomycin can be increased when it is combined with Pralsetinib. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pralsetinib. Darolutamide The serum concentration of Pralsetinib can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Pralsetinib can be increased when it is combined with Darunavir. Dasabuvir Dasabuvir may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Pralsetinib. Daunorubicin Pralsetinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Delafloxacin Pralsetinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Delavirdine The serum concentration of Pralsetinib can be increased when it is combined with Delavirdine. Desogestrel The metabolism of Desogestrel can be increased when combined with Pralsetinib. Desvenlafaxine The metabolism of Pralsetinib can be decreased when combined with Desvenlafaxine. Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Pralsetinib. Dexamethasone The serum concentration of Pralsetinib can be decreased when it is combined with Dexamethasone. Dexamethasone Dexamethasone acetate may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Dexibuprofen The metabolism of Dexibuprofen can be decreased when combined with Pralsetinib. Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Pralsetinib. Diazepam The metabolism of Diazepam can be decreased when combined with Pralsetinib. Diclofenac Pralsetinib may decrease the excretion rate of Diclofenac which could result in a higher serum level. Dicoumarol The metabolism of Dicoumarol can be decreased when combined with Pralsetinib. Didanosine The excretion of Didanosine can be decreased when combined with Pralsetinib. Dienogest The metabolism of Dienogest can be increased when combined with Pralsetinib. Diethylstilbestrol Pralsetinib may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Pralsetinib. Digoxin Pralsetinib may decrease the excretion rate of Digoxin which could result in a higher serum level. Dihydroergocornine The metabolism of Dihydroergocornine can be increased when combined with Pralsetinib. Dihydroergocristine Pralsetinib may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level. Dihydroergotamine The metabolism of Dihydroergotamine can be increased when combined with Pralsetinib. Diltiazem The metabolism of Pralsetinib can be decreased when combined with Diltiazem. Dinoprostone The excretion of Dinoprostone can be decreased when combined with Pralsetinib. Diosmin The serum concentration of Pralsetinib can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Diphenhydramine. Dipyridamole Pralsetinib may decrease the excretion rate of Dipyridamole which could result in a higher serum level. Disulfiram Pralsetinib may decrease the excretion rate of Disulfiram which could result in a higher serum level. Docetaxel The metabolism of Docetaxel can be increased when combined with Pralsetinib. Doconexent The metabolism of Doconexent can be decreased when combined with Pralsetinib. Dofetilide The metabolism of Dofetilide can be increased when combined with Pralsetinib. Dolutegravir Pralsetinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The metabolism of Domperidone can be decreased when combined with Pralsetinib. Donepezil Pralsetinib may decrease the excretion rate of Donepezil which could result in a higher serum level. Doravirine The metabolism of Doravirine can be decreased when combined with Pralsetinib. Doxazosin The metabolism of Doxazosin can be increased when combined with Pralsetinib. Doxepin The metabolism of Doxepin can be decreased when combined with Pralsetinib. Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Pralsetinib. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Pralsetinib. Dronedarone The serum concentration of Pralsetinib can be increased when it is combined with Dronedarone. Drospirenone The metabolism of Drospirenone can be increased when combined with Pralsetinib. Duloxetine The metabolism of Duloxetine can be decreased when combined with Pralsetinib. Dutasteride The metabolism of Dutasteride can be decreased when combined with Pralsetinib. Duvelisib Pralsetinib may decrease the excretion rate of Duvelisib which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Dyclonine. Ebastine The metabolism of Ebastine can be increased when combined with Pralsetinib. Econazole The serum concentration of Pralsetinib can be increased when it is combined with Econazole. Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Pralsetinib. Efavirenz The serum concentration of Pralsetinib can be increased when it is combined with Efavirenz. Elagolix The serum concentration of Pralsetinib can be increased when it is combined with Elagolix. Elbasvir Elbasvir may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Eletriptan The metabolism of Eletriptan can be decreased when combined with Pralsetinib. Elexacaftor The metabolism of Elexacaftor can be increased when combined with Pralsetinib. Eliglustat The metabolism of Eliglustat can be decreased when combined with Pralsetinib. Eltrombopag Eltrombopag may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Pralsetinib. Elvitegravir The serum concentration of Pralsetinib can be increased when it is combined with Elvitegravir. Emtricitabine The excretion of Emtricitabine can be decreased when combined with Pralsetinib. Enalapril The excretion of Enalapril can be decreased when combined with Pralsetinib. Enasidenib The serum concentration of Pralsetinib can be increased when it is combined with Enasidenib. Enfortumab The serum concentration of Enfortumab vedotin can be increased when it is combined with Pralsetinib. Entrectinib The metabolism of Entrectinib can be increased when combined with Pralsetinib. Enzalutamide The serum concentration of Pralsetinib can be decreased when it is combined with Enzalutamide. Eplerenone The metabolism of Eplerenone can be decreased when combined with Pralsetinib. Erdafitinib The serum concentration of Pralsetinib can be increased when it is combined with Erdafitinib. Ergotamine The serum concentration of Pralsetinib can be increased when it is combined with Ergotamine. Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Pralsetinib. Ertugliflozin Pralsetinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The serum concentration of Pralsetinib can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pralsetinib. Esketamine The metabolism of Esketamine can be decreased when combined with Pralsetinib. Estetrol The metabolism of Estetrol can be increased when combined with Pralsetinib. Estradiol Estradiol may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Estradiol acetate Estradiol acetate may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Estradiol benzoate Estradiol benzoate may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Estradiol cypionate Estradiol cypionate may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Estradiol dienanthate Estradiol dienanthate may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Estradiol valerate Estradiol valerate may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Estrone sulfate The metabolism of Estrone sulfate can be increased when combined with Pralsetinib. Eszopiclone The serum concentration of Eszopiclone can be decreased when it is combined with Pralsetinib. Ethinylestradiol The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Pralsetinib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Ethyl chloride. Ethynodiol diacetate The metabolism of Ethynodiol diacetate can be increased when combined with Pralsetinib. Etidocaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Etidocaine. Etodolac The metabolism of Etodolac can be decreased when combined with Pralsetinib. Etonogestrel The metabolism of Etonogestrel can be increased when combined with Pralsetinib. Etoposide The serum concentration of Etoposide can be increased when it is combined with Pralsetinib. Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Pralsetinib. Etravirine The metabolism of Etravirine can be decreased when combined with Pralsetinib. Everolimus The serum concentration of Pralsetinib can be increased when it is combined with Everolimus. Ezetimibe Pralsetinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Favipiravir The serum concentration of Pralsetinib can be increased when it is combined with Favipiravir. Febuxostat The excretion of Pralsetinib can be decreased when combined with Febuxostat. Fedratinib The serum concentration of Pralsetinib can be increased when it is combined with Fedratinib. Felodipine Pralsetinib may decrease the excretion rate of Felodipine which could result in a higher serum level. Fenofibrate Pralsetinib may decrease the excretion rate of Fenofibrate which could result in a higher serum level. Fentanyl The metabolism of Fentanyl can be decreased when combined with Pralsetinib. Fexinidazole The metabolism of Fexinidazole can be decreased when combined with Pralsetinib. Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Pralsetinib. Finasteride The metabolism of Finasteride can be decreased when combined with Pralsetinib. Finerenone The serum concentration of Finerenone can be increased when it is combined with Pralsetinib. Flecainide The excretion of Flecainide can be decreased when combined with Pralsetinib. Flibanserin The serum concentration of Pralsetinib can be increased when it is combined with Flibanserin. Flucloxacillin Pralsetinib may decrease the excretion rate of Flucloxacillin which could result in a higher serum level. Fluconazole The serum concentration of Pralsetinib can be increased when it is combined with Fluconazole. Fluindione The metabolism of Fluindione can be decreased when combined with Pralsetinib. Flunarizine The metabolism of Flunarizine can be decreased when combined with Pralsetinib. Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Pralsetinib. Fluorescein Pralsetinib may decrease the excretion rate of Fluorescein which could result in a higher serum level. Fluorouracil The metabolism of Fluorouracil can be decreased when combined with Pralsetinib. Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Pralsetinib. Flurbiprofen The metabolism of Flurbiprofen can be decreased when combined with Pralsetinib. Flutamide The metabolism of Flutamide can be decreased when combined with Pralsetinib. Fluticasone The metabolism of Fluticasone can be decreased when combined with Pralsetinib. Fluticasone furoate The metabolism of Fluticasone furoate can be decreased when combined with Pralsetinib. Fluticasone The metabolism of Fluticasone propionate can be decreased when combined with Pralsetinib. Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Pralsetinib. Fluvoxamine Pralsetinib may decrease the excretion rate of Fluvoxamine which could result in a higher serum level. Folic acid Pralsetinib may decrease the excretion rate of Folic acid which could result in a higher serum level. Formoterol The metabolism of Formoterol can be decreased when combined with Pralsetinib. Fosaprepitant The metabolism of Fosaprepitant can be increased when combined with Pralsetinib. Fosnetupitant The metabolism of Pralsetinib can be decreased when combined with Fosnetupitant. Fosphenytoin The serum concentration of Pralsetinib can be decreased when it is combined with Fosphenytoin. Fostamatinib Fostamatinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Fostemsavir Fostemsavir may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Fusidic acid The metabolism of Pralsetinib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Pralsetinib. Gadoxetic acid The excretion of Gadoxetic acid can be decreased when combined with Pralsetinib. Ganciclovir The excretion of Ganciclovir can be decreased when combined with Pralsetinib. Gefitinib Gefitinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Pralsetinib. Gestrinone The metabolism of Gestrinone can be increased when combined with Pralsetinib. Gilteritinib Gilteritinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Glasdegib The serum concentration of Pralsetinib can be increased when it is combined with Glasdegib. Glecaprevir The serum concentration of Pralsetinib can be increased when it is combined with Glecaprevir. Gliclazide The metabolism of Gliclazide can be decreased when combined with Pralsetinib. Glimepiride Pralsetinib may decrease the excretion rate of Glimepiride which could result in a higher serum level. Glipizide Pralsetinib may decrease the excretion rate of Glipizide which could result in a higher serum level. Gliquidone The metabolism of Gliquidone can be decreased when combined with Pralsetinib. Glyburide Pralsetinib may decrease the excretion rate of Glyburide which could result in a higher serum level. Glycyrrhizic acid Pralsetinib may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level. Grazoprevir Grazoprevir may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Grepafloxacin The excretion of Grepafloxacin can be decreased when combined with Pralsetinib. Guanidine The excretion of Guanidine can be decreased when combined with Pralsetinib. Halofantrine The metabolism of Halofantrine can be decreased when combined with Pralsetinib. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Pralsetinib. Halothane The metabolism of Halothane can be decreased when combined with Pralsetinib. Hydrocortisone The metabolism of Hydrocortisone can be decreased when combined with Pralsetinib. Hydrocortisone The metabolism of Hydrocortisone acetate can be decreased when combined with Pralsetinib. Hydrocortisone The metabolism of Hydrocortisone butyrate can be decreased when combined with Pralsetinib. Hydrocortisone The metabolism of Hydrocortisone cypionate can be decreased when combined with Pralsetinib. Hydrocortisone The metabolism of Hydrocortisone phosphate can be decreased when combined with Pralsetinib. Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Pralsetinib. Hydroxychloroquine The metabolism of Hydroxychloroquine can be decreased when combined with Pralsetinib. Hydroxyprogester The metabolism of Hydroxyprogesterone caproate can be increased when combined with Pralsetinib. Hydroxyzine The metabolism of Hydroxyzine can be decreased when combined with Pralsetinib. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Pralsetinib. Ibuprofen The metabolism of Ibuprofen can be decreased when combined with Pralsetinib. Idarubicin The metabolism of Idarubicin can be decreased when combined with Pralsetinib. Idelalisib The metabolism of Idelalisib can be increased when combined with Pralsetinib. Ifosfamide The metabolism of Ifosfamide can be increased when combined with Pralsetinib. Iloperidone The metabolism of Iloperidone can be decreased when combined with Pralsetinib. Imatinib Pralsetinib may decrease the excretion rate of Imatinib which could result in a higher serum level. Imipramine The serum concentration of Imipramine can be increased when it is combined with Pralsetinib. Indacaterol The serum concentration of Indacaterol can be increased when it is combined with Pralsetinib. Indinavir The serum concentration of Pralsetinib can be increased when it is combined with Indinavir. Indocyanine Pralsetinib may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level. Indomethacin Pralsetinib may decrease the excretion rate of Indomethacin which could result in a higher serum level. Infigratinib The metabolism of Infigratinib can be increased when combined with Pralsetinib. Inotuzumab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pralsetinib. Irbesartan The metabolism of Irbesartan can be decreased when combined with Pralsetinib. Irinotecan The metabolism of Irinotecan can be increased when combined with Pralsetinib. Isavuconazole The serum concentration of Pralsetinib can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Pralsetinib can be increased when it is combined with Isavuconazonium. Isoniazid The metabolism of Pralsetinib can be decreased when combined with Isoniazid. Isradipine Pralsetinib may decrease the excretion rate of Isradipine which could result in a higher serum level. Istradefylline The serum concentration of Pralsetinib can be increased when it is combined with Istradefylline. Itraconazole The serum concentration of Pralsetinib can be increased when it is combined with Itraconazole. Ivacaftor The serum concentration of Pralsetinib can be increased when it is combined with Ivacaftor. Ivermectin Pralsetinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The metabolism of Pralsetinib can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Pralsetinib can be increased when it is combined with Ixabepilone. Ixazomib The metabolism of Ixazomib can be increased when combined with Pralsetinib. Ketamine The metabolism of Ketamine can be decreased when combined with Pralsetinib. Ketoconazole The serum concentration of Pralsetinib can be increased when it is combined with Ketoconazole. Ketorolac The metabolism of Ketorolac can be decreased when combined with Pralsetinib. Lacosamide The metabolism of Lacosamide can be increased when combined with Pralsetinib. Lamivudine Pralsetinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lansoprazole Lansoprazole may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Lapatinib The serum concentration of Pralsetinib can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Pralsetinib. Lasmiditan The serum concentration of Pralsetinib can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Pralsetinib. Lefamulin Pralsetinib may decrease the excretion rate of Lefamulin which could result in a higher serum level. Leflunomide Pralsetinib may decrease the excretion rate of Leflunomide which could result in a higher serum level. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Pralsetinib. Lenvatinib Pralsetinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. Lercanidipine The metabolism of Lercanidipine can be decreased when combined with Pralsetinib. Lesinurad The metabolism of Lesinurad can be decreased when combined with Pralsetinib. Letermovir Letermovir may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Levacetylmethadol The metabolism of Levacetylmethadol can be increased when combined with Pralsetinib. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Pralsetinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Levobupivacaine. Levofloxacin The excretion of Levofloxacin can be decreased when combined with Pralsetinib. Levoketoconazole The serum concentration of Pralsetinib can be increased when it is combined with Levoketoconazole. Levomilnacipran The metabolism of Levomilnacipran can be increased when combined with Pralsetinib. Levonorgestrel The metabolism of Levonorgestrel can be increased when combined with Pralsetinib. Levosalbutamol The excretion of Levosalbutamol can be decreased when combined with Pralsetinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Lidocaine. Linagliptin The serum concentration of Pralsetinib can be increased when it is combined with Linagliptin. Liothyronine The excretion of Liothyronine can be decreased when combined with Pralsetinib. Liotrix The excretion of Liotrix can be decreased when combined with Pralsetinib. Lomitapide The serum concentration of Pralsetinib can be increased when it is combined with Lomitapide. Lonafarnib The serum concentration of Pralsetinib can be increased when it is combined with Lonafarnib. Loncastuximab The serum concentration of Loncastuximab tesirine can be increased when it is combined with Pralsetinib. Loperamide The excretion of Loperamide can be decreased when combined with Pralsetinib. Lopinavir The serum concentration of Pralsetinib can be increased when it is combined with Lopinavir. Loratadine Pralsetinib may decrease the excretion rate of Loratadine which could result in a higher serum level. Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Pralsetinib. Lornoxicam The metabolism of Lornoxicam can be decreased when combined with Pralsetinib. Losartan Pralsetinib may decrease the excretion rate of Losartan which could result in a higher serum level. Lovastatin The metabolism of Lovastatin can be decreased when combined with Pralsetinib. Loxapine The serum concentration of Pralsetinib can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Pralsetinib can be increased when it is combined with Lumacaftor. Lumateperone The serum concentration of Lumateperone can be decreased when it is combined with Pralsetinib. Lumiracoxib The metabolism of Lumiracoxib can be decreased when combined with Pralsetinib. Lusutrombopag Pralsetinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Lynestrenol The metabolism of Lynestrenol can be increased when combined with Pralsetinib. Mannitol The serum concentration of Mannitol can be increased when it is combined with Pralsetinib. Maribavir The serum concentration of Pralsetinib can be increased when it is combined with Maribavir. Mavacamten The serum concentration of Pralsetinib can be decreased when it is combined with Mavacamten. Medroxyprogestero The metabolism of Medroxyprogesterone acetate can be increased when combined with Pralsetinib. Mefenamic acid The metabolism of Mefenamic acid can be decreased when combined with Pralsetinib. Mefloquine The serum concentration of Pralsetinib can be increased when it is combined with Mefloquine. Megestrol acetate The metabolism of Megestrol acetate can be increased when combined with Pralsetinib. Meloxicam The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Meloxicam. Meperidine The metabolism of Meperidine can be increased when combined with Pralsetinib. Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Pralsetinib. Mepivacaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Mepivacaine. Mestranol The metabolism of Mestranol can be increased when combined with Pralsetinib. Metformin The excretion of Metformin can be decreased when combined with Pralsetinib. Methadone The metabolism of Methadone can be decreased when combined with Pralsetinib. Methimazole The serum concentration of Pralsetinib can be increased when it is combined with Methimazole. Methotrexate The metabolism of Methotrexate can be increased when combined with Pralsetinib. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pralsetinib. Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Pralsetinib. Methylene blue The serum concentration of Pralsetinib can be increased when it is combined with Methylene blue. Methylprednisone The metabolism of Methylprednisone can be increased when combined with Pralsetinib. Methysergide The metabolism of Methysergide can be increased when combined with Pralsetinib. Metreleptin The metabolism of Pralsetinib can be increased when combined with Metreleptin. Metronidazole The metabolism of Metronidazole can be decreased when combined with Pralsetinib. Miconazole The metabolism of Pralsetinib can be decreased when combined with Miconazole. Midazolam The serum concentration of Midazolam can be increased when it is combined with Pralsetinib. Midostaurin The serum concentration of Pralsetinib can be increased when it is combined with Midostaurin. Mifepristone The serum concentration of Pralsetinib can be increased when it is combined with Mifepristone. Milnacipran The metabolism of Milnacipran can be increased when combined with Pralsetinib. Mirabegron The serum concentration of Pralsetinib can be increased when it is combined with Mirabegron. Mitapivat The serum concentration of Pralsetinib can be increased when it is combined with Mitapivat. Mitotane The serum concentration of Pralsetinib can be decreased when it is combined with Mitotane. Mitoxantrone Pralsetinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Mobocertinib The metabolism of Mobocertinib can be decreased when combined with Pralsetinib. Modafinil The metabolism of Modafinil can be decreased when combined with Pralsetinib. Montelukast The metabolism of Montelukast can be decreased when combined with Pralsetinib. Morphine The serum concentration of Morphine can be increased when it is combined with Pralsetinib. Mycophenolate Pralsetinib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. Nabilone The metabolism of Nabilone can be decreased when combined with Pralsetinib. Nabumetone The metabolism of Nabumetone can be decreased when combined with Pralsetinib. Nadolol The excretion of Nadolol can be decreased when combined with Pralsetinib. Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Pralsetinib. Naloxone The serum concentration of Pralsetinib can be increased when it is combined with Naloxone. Naproxen Pralsetinib may decrease the excretion rate of Naproxen which could result in a higher serum level. Nateglinide The metabolism of Nateglinide can be decreased when combined with Pralsetinib. Nefazodone The serum concentration of Pralsetinib can be increased when it is combined with Nefazodone. Nelfinavir The serum concentration of Pralsetinib can be increased when it is combined with Nelfinavir. Neratinib The serum concentration of Pralsetinib can be increased when it is combined with Neratinib. Netupitant The serum concentration of Pralsetinib can be increased when it is combined with Netupitant. Nevirapine The metabolism of Nevirapine can be decreased when combined with Pralsetinib. Nicardipine Pralsetinib may decrease the excretion rate of Nicardipine which could result in a higher serum level. Niclosamide The metabolism of Niclosamide can be decreased when combined with Pralsetinib. Nifedipine Pralsetinib may decrease the excretion rate of Nifedipine which could result in a higher serum level. Nilotinib The serum concentration of Pralsetinib can be increased when it is combined with Nilotinib. Nilvadipine The metabolism of Pralsetinib can be decreased when combined with Nilvadipine. Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Pralsetinib. Nisoldipine The metabolism of Nisoldipine can be decreased when combined with Pralsetinib. Nitrendipine Pralsetinib may decrease the excretion rate of Nitrendipine which could result in a higher serum level. Nitrofurantoin Pralsetinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nomegestrol The metabolism of Nomegestrol can be increased when combined with Pralsetinib. Nomegestrol acetate The metabolism of Nomegestrol acetate can be increased when combined with Pralsetinib. Norelgestromin The metabolism of Norelgestromin can be increased when combined with Pralsetinib. Norethisterone The metabolism of Norethisterone can be increased when combined with Pralsetinib. Norethynodrel The metabolism of Norethynodrel can be increased when combined with Pralsetinib. Norgestimate The serum concentration of Pralsetinib can be increased when it is combined with Norgestimate. Norgestrel The metabolism of Norgestrel can be increased when combined with Pralsetinib. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Pralsetinib. Novobiocin Novobiocin may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Obeticholic acid The risk or severity of adverse effects can be increased when Pralsetinib is combined with Obeticholic acid. Ofloxacin Pralsetinib may decrease the excretion rate of Ofloxacin which could result in a higher serum level. Olaparib The metabolism of Olaparib can be increased when combined with Pralsetinib. Oliceridine The serum concentration of Oliceridine can be decreased when it is combined with Pralsetinib. Olmesartan The risk or severity of liver damage can be increased when Olmesartan is combined with Pralsetinib. Olodaterol The metabolism of Olodaterol can be decreased when combined with Pralsetinib. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Pralsetinib. Ombitasvir Pralsetinib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. Omeprazole Omeprazole may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Ondansetron The metabolism of Ondansetron can be decreased when combined with Pralsetinib. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Pralsetinib. Ospemifene The metabolism of Ospemifene can be decreased when combined with Pralsetinib. Oteseconazole The serum concentration of Pralsetinib can be increased when it is combined with Oteseconazole. Ouabain The excretion of Ouabain can be decreased when combined with Pralsetinib. Oxaliplatin Pralsetinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Oxetacaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Pralsetinib. Oxycodone The metabolism of Oxycodone can be decreased when combined with Pralsetinib. Ozanimod Pralsetinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The metabolism of Paclitaxel can be increased when combined with Pralsetinib. Pacritinib The serum concentration of Pralsetinib can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Pralsetinib can be increased when it is combined with Palbociclib. Paliperidone The serum concentration of Pralsetinib can be increased when it is combined with Paliperidone. Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Pralsetinib. Pantoprazole Pantoprazole may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Paramethadione The metabolism of Paramethadione can be decreased when combined with Pralsetinib. Parecoxib The metabolism of Parecoxib can be decreased when combined with Pralsetinib. Paritaprevir Paritaprevir may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Pralsetinib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Pralsetinib. Penicillamine The excretion of Penicillamine can be decreased when combined with Pralsetinib. Pentamidine The metabolism of Pentamidine can be decreased when combined with Pralsetinib. Pentobarbital The serum concentration of Pralsetinib can be decreased when it is combined with Pentobarbital. Perampanel The metabolism of Perampanel can be increased when combined with Pralsetinib. Pexidartinib The metabolism of Pexidartinib can be increased when combined with Pralsetinib. Phenobarbital The serum concentration of Pralsetinib can be decreased when it is combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be increased when combined with Pralsetinib. Phenylbutazone The metabolism of Phenylbutazone can be decreased when combined with Pralsetinib. Phenytoin The serum concentration of Pralsetinib can be decreased when it is combined with Phenytoin. Pibrentasvir The serum concentration of Pralsetinib can be increased when it is combined with Pibrentasvir. Pimavanserin The metabolism of Pimavanserin can be increased when combined with Pralsetinib. Pimozide The metabolism of Pimozide can be increased when combined with Pralsetinib. Pioglitazone The metabolism of Pioglitazone can be increased when combined with Pralsetinib. Piperaquine The metabolism of Piperaquine can be decreased when combined with Pralsetinib. Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Pralsetinib. Piroxicam The metabolism of Piroxicam can be decreased when combined with Pralsetinib. Pitavastatin Pralsetinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Pitolisant The serum concentration of Pralsetinib can be decreased when it is combined with Pitolisant. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Pralsetinib. Ponatinib The serum concentration of Pralsetinib can be increased when it is combined with Ponatinib. Ponesimod The metabolism of Ponesimod can be decreased when combined with Pralsetinib. Posaconazole The serum concentration of Pralsetinib can be increased when it is combined with Posaconazole. Pralatrexate Pralsetinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pramocaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Pramocaine. Prasugrel The metabolism of Prasugrel can be decreased when combined with Pralsetinib. Pravastatin Pralsetinib may decrease the excretion rate of Pravastatin which could result in a higher serum level. Praziquantel The metabolism of Praziquantel can be decreased when combined with Pralsetinib. Prazosin Pralsetinib may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednisolone The serum concentration of Prednisolone phosphate can be increased when it is combined with Pralsetinib. Pretomanid The metabolism of Pretomanid can be increased when combined with Pralsetinib. Prilocaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Prilocaine. Primaquine The metabolism of Pralsetinib can be decreased when combined with Primaquine. Primidone The serum concentration of Pralsetinib can be decreased when it is combined with Primidone. Procainamide The excretion of Procainamide can be decreased when combined with Pralsetinib. Procaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Procaine. Progesterone Progesterone may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Proguanil The metabolism of Proguanil can be decreased when combined with Pralsetinib. Promazine The metabolism of Promazine can be decreased when combined with Pralsetinib. Propafenone The serum concentration of Pralsetinib can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Proparacaine. Propofol The metabolism of Propofol can be decreased when combined with Pralsetinib. Propoxycaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Propoxycaine. Propranolol The metabolism of Propranolol can be decreased when combined with Pralsetinib. Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Pralsetinib. Quazepam The metabolism of Quazepam can be decreased when combined with Pralsetinib. Quetiapine The metabolism of Quetiapine can be decreased when combined with Pralsetinib. Quinidine The serum concentration of Pralsetinib can be increased when it is combined with Quinidine. Quinine The serum concentration of Pralsetinib can be increased when it is combined with Quinine. Rabeprazole Rabeprazole may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Raloxifene Pralsetinib may decrease the excretion rate of Raloxifene which could result in a higher serum level. Ramelteon The metabolism of Ramelteon can be decreased when combined with Pralsetinib. Ranitidine The excretion of Ranitidine can be decreased when combined with Pralsetinib. Ranolazine The metabolism of Ranolazine can be increased when combined with Pralsetinib. Regorafenib The serum concentration of Pralsetinib can be increased when it is combined with Regorafenib. Relebactam The excretion of Relebactam can be decreased when combined with Pralsetinib. Relugolix The serum concentration of Relugolix can be increased when it is combined with Pralsetinib. Repaglinide Pralsetinib may decrease the excretion rate of Repaglinide which could result in a higher serum level. Reserpine The serum concentration of Pralsetinib can be increased when it is combined with Reserpine. Retapamulin The metabolism of Retapamulin can be decreased when combined with Pralsetinib. Revefenacin Pralsetinib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The serum concentration of Pralsetinib can be increased when it is combined with Ribociclib. Rifampicin The serum concentration of Pralsetinib can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Pralsetinib can be increased when it is combined with Rifamycin. Rifapentine The serum concentration of Pralsetinib can be decreased when it is combined with Rifapentine. Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Pralsetinib. Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Pralsetinib. Riluzole Pralsetinib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The metabolism of Rimegepant can be increased when combined with Pralsetinib. Rimexolone The serum concentration of Pralsetinib can be decreased when it is combined with Rimexolone. Riociguat Pralsetinib may decrease the excretion rate of Riociguat which could result in a higher serum level. Ripretinib The serum concentration of Pralsetinib can be increased when it is combined with Ripretinib. Risperidone The metabolism of Risperidone can be decreased when combined with Pralsetinib. Ritonavir The serum concentration of Pralsetinib can be increased when it is combined with Ritonavir. Rivaroxaban Pralsetinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Pralsetinib. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Pralsetinib. Rolapitant The serum concentration of Pralsetinib can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Pralsetinib. Ropivacaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Ropivacaine. Rosiglitazone Pralsetinib may decrease the excretion rate of Rosiglitazone which could result in a higher serum level. Rosuvastatin Pralsetinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. Roxadustat The serum concentration of Pralsetinib can be increased when it is combined with Roxadustat. Rucaparib Rucaparib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Rupatadine The metabolism of Rupatadine can be decreased when combined with Pralsetinib. Ruxolitinib The metabolism of Ruxolitinib can be increased when combined with Pralsetinib. Safinamide Safinamide may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Salicylic acid The metabolism of Salicylic acid can be decreased when combined with Pralsetinib. Salmeterol The metabolism of Salmeterol can be decreased when combined with Pralsetinib. Sapropterin The serum concentration of Pralsetinib can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Pralsetinib can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Pralsetinib can be increased when it is combined with Sarecycline. Satralizumab The serum concentration of Pralsetinib can be decreased when it is combined with Satralizumab. Saxagliptin The metabolism of Saxagliptin can be decreased when combined with Pralsetinib. Segesterone The metabolism of Segesterone acetate can be increased when combined with Pralsetinib. Selegiline The metabolism of Selegiline can be decreased when combined with Pralsetinib. Selexipag The serum concentration of Selexipag can be increased when it is combined with Pralsetinib. Selpercatinib The serum concentration of Selpercatinib can be increased when it is combined with Pralsetinib. Selumetinib Pralsetinib may decrease the excretion rate of Selumetinib which could result in a higher serum level. Sertraline The metabolism of Sertraline can be decreased when combined with Pralsetinib. Sildenafil The serum concentration of Pralsetinib can be increased when it is combined with Sildenafil. Silodosin The excretion of Silodosin can be decreased when combined with Pralsetinib. Simeprevir The serum concentration of Pralsetinib can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Pralsetinib can be increased when it is combined with Simvastatin. Sincalide The excretion of Sincalide can be decreased when combined with Pralsetinib. Siponimod The metabolism of Siponimod can be increased when combined with Pralsetinib. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Pralsetinib. Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Pralsetinib. Sitaxentan The metabolism of Sitaxentan can be decreased when combined with Pralsetinib. Sofosbuvir Pralsetinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solriamfetol The excretion of Solriamfetol can be decreased when combined with Pralsetinib. Somatrogon The metabolism of Pralsetinib can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be increased when combined with Pralsetinib. Sorafenib The serum concentration of Pralsetinib can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Pralsetinib can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Pralsetinib can be increased when it is combined with Sotorasib. Spironolactone Pralsetinib may decrease the excretion rate of Spironolactone which could result in a higher serum level. St. John's Wort The serum concentration of Pralsetinib can be decreased when it is combined with St. John's Wort. Stavudine The excretion of Stavudine can be decreased when combined with Pralsetinib. Stiripentol The serum concentration of Pralsetinib can be increased when it is combined with Stiripentol. Sulfadiazine The metabolism of Sulfadiazine can be decreased when combined with Pralsetinib. Sulfamethoxazole Pralsetinib may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level. Sulfasalazine Sulfasalazine may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Sulfinpyrazone Pralsetinib may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level. Sumatriptan Pralsetinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The metabolism of Sunitinib can be increased when combined with Pralsetinib. Suvorexant The serum concentration of Pralsetinib can be increased when it is combined with Suvorexant. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Pralsetinib. Tadalafil The metabolism of Tadalafil can be decreased when combined with Pralsetinib. Tafamidis The serum concentration of Pralsetinib can be increased when it is combined with Tafamidis. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Pralsetinib. Tamoxifen The serum concentration of Pralsetinib can be increased when it is combined with Tamoxifen. Tasimelteon The metabolism of Tasimelteon can be increased when combined with Pralsetinib. Taurocholic acid Pralsetinib may decrease the excretion rate of Taurocholic acid which could result in a higher serum level. Tazarotene The metabolism of Tazarotene can be decreased when combined with Pralsetinib. Tazemetostat Pralsetinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. Tazobactam The excretion of Tazobactam can be decreased when combined with Pralsetinib. Technetium The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Pralsetinib. Technetium The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Pralsetinib. Tegafur The metabolism of Tegafur can be decreased when combined with Pralsetinib. Tegaserod Pralsetinib may decrease the excretion rate of Tegaserod which could result in a higher serum level. Telaprevir The serum concentration of Pralsetinib can be increased when it is combined with Telaprevir. Telithromycin The serum concentration of Pralsetinib can be increased when it is combined with Telithromycin. Telmisartan Pralsetinib may decrease the excretion rate of Telmisartan which could result in a higher serum level. Telotristat ethyl The serum concentration of Pralsetinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Pralsetinib can be increased when it is combined with Temsirolimus. Teniposide The metabolism of Teniposide can be increased when combined with Pralsetinib. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pralsetinib. Tenofovir disoproxil The serum concentration of Tenofovir disoproxil can be increased when it is combined with Pralsetinib. Tenoxicam The metabolism of Tenoxicam can be decreased when combined with Pralsetinib. Tepotinib The serum concentration of Tepotinib can be increased when it is combined with Pralsetinib. Terbinafine The metabolism of Terbinafine can be decreased when combined with Pralsetinib. Terfenadine The serum concentration of Pralsetinib can be increased when it is combined with Terfenadine. Teriflunomide Teriflunomide may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Testosterone Pralsetinib may decrease the excretion rate of Testosterone which could result in a higher serum level. Testosterone Pralsetinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone Pralsetinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Tetracaine The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Tetracaine. Tezacaftor The serum concentration of Tezacaftor can be increased when it is combined with Pralsetinib. Thalidomide The metabolism of Thalidomide can be decreased when combined with Pralsetinib. Theophylline The metabolism of Theophylline can be increased when combined with Pralsetinib. Thiamylal The metabolism of Thiamylal can be decreased when combined with Pralsetinib. Thiotepa The metabolism of Thiotepa can be increased when combined with Pralsetinib. Ticagrelor The serum concentration of Pralsetinib can be increased when it is combined with Ticagrelor. Tinidazole Pralsetinib may decrease the excretion rate of Tinidazole which could result in a higher serum level. Tipranavir The serum concentration of Pralsetinib can be increased when it is combined with Tipranavir. Tivozanib The metabolism of Tivozanib can be increased when combined with Pralsetinib. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Pralsetinib. Tolazamide The metabolism of Tolazamide can be decreased when combined with Pralsetinib. Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Pralsetinib. Tolterodine The metabolism of Tolterodine can be decreased when combined with Pralsetinib. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Pralsetinib. Topotecan The serum concentration of Topotecan can be increased when it is combined with Pralsetinib. Torasemide The metabolism of Torasemide can be decreased when combined with Pralsetinib. Toremifene The serum concentration of Pralsetinib can be increased when it is combined with Toremifene. Trabectedin The metabolism of Trabectedin can be increased when combined with Pralsetinib. Tramadol The metabolism of Tramadol can be decreased when combined with Pralsetinib. Trastuzumab The serum concentration of Trastuzumab emtansine can be increased when it is combined with Pralsetinib. Trazodone The metabolism of Trazodone can be decreased when combined with Pralsetinib. Treprostinil The metabolism of Treprostinil can be decreased when combined with Pralsetinib. Tretinoin The metabolism of Tretinoin can be decreased when combined with Pralsetinib. Triamcinolone The metabolism of Triamcinolone can be decreased when combined with Pralsetinib. Triazolam The metabolism of Triazolam can be decreased when combined with Pralsetinib. Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Pralsetinib. Trifluridine The excretion of Trifluridine can be decreased when combined with Pralsetinib. Trilaciclib Pralsetinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimethadione The metabolism of Trimethadione can be decreased when combined with Pralsetinib. Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Pralsetinib. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Pralsetinib. Troglitazone The risk or severity of liver damage can be increased when Troglitazone is combined with Pralsetinib. Troleandomycin The serum concentration of Pralsetinib can be increased when it is combined with Troleandomycin. Tucatinib Tucatinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Pralsetinib. Udenafil The metabolism of Udenafil can be decreased when combined with Pralsetinib. Ulipristal The metabolism of Ulipristal can be increased when combined with Pralsetinib. Umbralisib The serum concentration of Pralsetinib can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Pralsetinib. Ursodeoxycholic acid Pralsetinib may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level. Valbenazine The metabolism of Valbenazine can be decreased when combined with Pralsetinib. Valdecoxib The metabolism of Valdecoxib can be decreased when combined with Pralsetinib. Valproic acid The metabolism of Valproic acid can be decreased when combined with Pralsetinib. Valsartan The metabolism of Valsartan can be decreased when combined with Pralsetinib. Vandetanib The serum concentration of Pralsetinib can be increased when it is combined with Vandetanib. Vardenafil The metabolism of Vardenafil can be decreased when combined with Pralsetinib. Velpatasvir The serum concentration of Pralsetinib can be increased when it is combined with Velpatasvir. Vemurafenib The serum concentration of Pralsetinib can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Pralsetinib can be increased when it is combined with Venetoclax. Venlafaxine Venlafaxine may increase the excretion rate of Pralsetinib which could result in a lower serum level and potentially a reduction in efficacy. Verapamil The serum concentration of Pralsetinib can be increased when it is combined with Verapamil. Viloxazine The metabolism of Pralsetinib can be decreased when combined with Viloxazine. Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Pralsetinib. Vincristine The excretion of Vincristine can be decreased when combined with Pralsetinib. Vindesine The metabolism of Vindesine can be increased when combined with Pralsetinib. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Pralsetinib. Vinorelbine The metabolism of Vinorelbine can be increased when combined with Pralsetinib. Vismodegib Vismodegib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Voclosporin The serum concentration of Pralsetinib can be increased when it is combined with Voclosporin. Vonoprazan The metabolism of Vonoprazan can be decreased when combined with Pralsetinib. Vorapaxar The serum concentration of Pralsetinib can be increased when it is combined with Vorapaxar. Voriconazole The serum concentration of Pralsetinib can be increased when it is combined with Voriconazole. Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Pralsetinib. Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Pralsetinib. Voxilaprevir The serum concentration of Pralsetinib can be increased when it is combined with Voxilaprevir. Warfarin The serum concentration of Warfarin can be increased when it is combined with Pralsetinib. Ximelagatran The metabolism of Ximelagatran can be decreased when combined with Pralsetinib. Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Pralsetinib. Zalcitabine The excretion of Zalcitabine can be decreased when combined with Pralsetinib. Zaleplon The metabolism of Zaleplon can be decreased when combined with Pralsetinib. Zanubrutinib The metabolism of Zanubrutinib can be increased when combined with Pralsetinib. Zidovudine Pralsetinib may decrease the excretion rate of Zidovudine which could result in a higher serum level. Zileuton The metabolism of Zileuton can be decreased when combined with Pralsetinib. Zimelidine The metabolism of Pralsetinib can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Pralsetinib can be decreased when combined with Ziprasidone. Zolpidem The metabolism of Zolpidem can be increased when combined with Pralsetinib. Zonisamide The serum concentration of Pralsetinib can be increased when it is combined with Zonisamide. Zopiclone The metabolism of Zopiclone can be decreased when combined with Pralsetinib. Zuclopenthixol The metabolism of Zuclopenthixol can be increased when combined with Pralsetinib. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on findings from animal studies and its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman. Pregnancy status should be verified prior to initiating therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Females of reproductive potential should use effective nonhormonal contraception during therapy and for 2 weeks after; this drug may render hormonal contraceptives ineffective. Male patients with female partners of reproductive potential should use effective contraception during therapy and for 1 week after the final dose. Lactation There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. How should this medicine be used?

Pralsetinib comes as a capsule to take by mouth. It is usually taken once daily on an empty stomach, at least 2 hours before and at least 1 hour after a meal. Take pralsetinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take pralsetinib exactly as directed. Do not take more or less of it or take it more…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)